<DOC>
	<DOCNO>NCT00077285</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan carboplatin , work different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This phase II trial study well give irinotecan together carboplatin upfront window therapy ( first-line therapy ) work treat patient newly diagnose intermediate-risk high-risk rhabdomyosarcoma .</brief_summary>
	<brief_title>Irinotecan Carboplatin Upfront Window Therapy Treating Patients With Newly Diagnosed Intermediate-Risk High-Risk Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient newly diagnose intermediate- high-risk rhabdomyosarcoma treat upfront window therapy comprise irinotecan carboplatin . - Determine acute toxic effect regimen combine radiotherapy patient . - Determine safety feasibility regimen patient . - Determine rate local control achieve patient treated regimen combination intensity-modulated radiotherapy . - Determine safety feasibility administer maintenance therapy comprise irinotecan patient high-risk rhabdomyosarcoma treat regimen . Secondary - Correlate , preliminarily , vitro measurement angiogenesis clinical feature ( extent disease ) , response therapy , outcome patient treat regimen . - Determine , preliminarily , efficacy regimen , term improve outcome , patient . OUTLINE : This pilot study . - Courses 1 2 : Patients receive carboplatin IV 1 hour day 1 irinotecan IV 1 hour day 1-5 8-12 . Treatment repeat every 21 day total 2 course . - Courses 3-5 : Patients receive vincristine IV day 1 , 8 , 15 ; dexrazoxane IV 15-30 minute , doxorubicin IV 15-30 minute , cyclophosphamide IV 1 hour day 1 2 ; filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin approximately day 3 continue blood count recover . Treatment repeat every 21 day total 3 course . Some patient may undergo surgical resection tumor completion course 5 . After course 5 , patient undergo radiotherapy daily , 5 day week , 4-5.5 week . - Courses 6 7* : Patients receive vincristine IV carboplatin IV 1 hour day 1 ; irinotecan IV 1 hour day 1-5 8-12 ; G-CSF SC daily begin approximately day 13 continue blood count recover . Treatment repeat every 21 day total 2 course . NOTE : *Patients develop disease progression course 1 2 receive irinotecan carboplatin . Instead , patient receive ifosfamide etoposide course 8 9 . - Courses 8 9 : Patients receive vincristine IV day 1 ; etoposide IV 1 hour ifosfamide IV 2 hour day 1-5 ; G-CSF SC daily begin approximately day 6 continue blood count recover . Treatment repeat every 21 day total 2 course . - Course 10 : Patients receive vincristine IV day 1 , 8 , 15 , 22 , 29 , 36 , 43 ; dexrazoxane IV 15-30 minute , doxorubicin IV 15-30 minute , cyclophosphamide IV 1 hour day 1 2 ; filgrastim SC begin approximately day 3 continue blood count recover ( 1 course ) . - Course 11 12 : Patients receive etoposide IV 1 hour ifosfamide IV 2 hour day 1-5 G-CSF SC daily begin approximately day 6 continue blood count recover . Treatment repeat every 21 day total 2 course . Patients high-risk disease proceed maintenance therapy . - Maintenance therapy* : Patients receive irinotecan IV 1 hour day 1-5 8-12 . Treatment repeat every 21 day total 6 course . NOTE : *Patients develop disease progression course 1 2 receive irinotecan . In course , treatment continue absence unacceptable toxicity disease progression recurrence initial response . Patients follow monthly 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . *Starting A ( 8 ) , patient undergo PET Scans instead Bone Scans , discretion PI .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>INCLUSION CRITERIA : Newly diagnose , previously untreated histologicallyproven rhabdomyosarcoma , undifferentiated sarcoma , ectomesenchymoma . Histology must confirm MSKCC pathologist . Intermediate highrisk feature define : All patient Stage 4 tumor ( distant metastasis ) . Intermediate Risk : All patient nonmetastatic undifferentiated sarcoma alveolar RMS ectomesenchymoma alveolar feature ( regardless age , site , size , stage , degree initial surgical resection ) ; All patient &lt; 1 year age nonmetastatic embryonal RMS ectomesenchymoma embryonal feature ( regardless site , stage , degree initial surgical resection ) . Patients ≥ 1 year age Stage 2 3 ( unfavorable site [ see Appendix I ] either size &gt; 5 cm , OR regional node positive , ) , Group III ( gross residual disease postbiopsy attempt resection ) embryonal RMS ectomesenchymoma embryonal feature Age : ≤ 50 year ( inclusive ) time diagnosis . Biopsy definitive surgery within 42 day start treatment . Organ function : Normal renal function : Normal serum creatinine age creatinine clearance nuclear GFR ≥ 80 ml/min/1.73m2 ( absence obstructive hydronephrosis , e.g. , pelvic bladder/prostate tumor ) . Normal liver function : Total bilirubin , SGOT/SGPT &lt; 2.5 time upper limit normal ( absence hepatic involvement tumor ) Normal cardiac function : echocardiogram shorten fraction ≥ 28 % resting leave ventricular ejection fraction ( LVEF ) ≥ 50 % Technetium99m pertechnetate radionuclide cineangiography ( MUGA ) Normal hematologic function : absolute neutrophil count ( ANC ) ≥ 1500/μL , hemoglobin ≥ 9 gm/dL , platelet count ≥ 100,000/μL ( absence bone marrow infiltration tumor presence disseminate intravascular coagulation ) . Measurable disease require . Patients must consent indwell central venous catheter . Sexually active patient childbearing potential must willing use effective method contraception . Patient guardian must capable provide informed consent . SUBJECT EXCLUSION CRITERIA : Prior chemotherapy radiotherapy ( limited , emergent radiotherapy treatment threaten airway cord compromise ) . Pregnant breast feeding female chemotherapy administer trial could detrimental effect develop fetus newborn .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>alveolar childhood rhabdomyosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>childhood malignant mesenchymoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage I adult soft tissue sarcoma</keyword>
</DOC>